On Wednesday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $28.24 which represents a decrease of $-0.14 or -0.49% from the prior close of $28.38. The stock opened at $28.23 and ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

At recent prices, $100 is enough to buy shares of both Royalty Pharma and AT&T. AT&T offers a high dividend yield, and it ...

Royalty Pharma plc (NASDAQ:RPRX), a company specializing in pharmaceutical preparations, announced a significant milestone following the U.S. Food and Drug Administration's (FDA) approval of a new ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

US antivirals giant Gilead Sciences today announced that it has signed non-exclusive, royalty-free voluntary licensing ...

Royalty Pharma plc (NASDAQ:RPRX), a company specializing in pharmaceutical preparations, announced a significant milestone following the U.S. Food and Drug Administration's (FDA) approval of a new ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

Most readers would already be aware that Royalty Pharma's (NASDAQ:RPRX) stock increased significantly by 6.7% over the... Proceeds to support continued development and commercialization of ...

Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration ...